DERM vs PFE

Journey Medical (DERM) maintains its high-risk, high-reward profile, primarily driven by the upcoming PDUFA decision for DFD-29 in Q3 2026. The Q1 2026 earnings report showed positive signs with a revenue beat ($15.96M vs. $15.47M consensus), 21% YoY growth, narrowing losses (EPS $(0.08)$ vs $(0.18)$ YoY), and positive Adjusted EBITDA of $0.62M. Cash and equivalents also increased to $27.22M, prov...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...